Standard BioTools Inc.

LAB

Precision medicineGenomic analysis

$0.67vs prev close▲+0.00(+0.09%)

$0.6352W Range$1.72

4% from low

-0.16 (-19.28%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.00%

1M -0.03%p

Holding ETFs

1 ETFs

ARKG

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -100.0% · Market value -100.0% · Weight -0.03%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.03.18	SELL	ARKG	189	$0.96	$182
26.03.13	SELL	ARKG	1,437	$0.93	$1.3K
26.03.12	SELL	ARKG	12,801	$0.93	$11.9K
26.03.11	SELL	ARKG	102,053	$0.97	$99.0K
26.03.10	SELL	ARKG	136,193	$0.99	$134.8K
26.03.09	SELL	ARKG	186,633	$0.99	$184.0K
26.03.06	SELL	ARKG	397,382	$0.99	$393.5K
26.03.05	SELL	ARKG	129,759	$1.02	$132.4K
26.03.04	SELL	ARKG	473,801	$1.06	$502.2K
26.03.03	SELL	ARKG	1,484,403	$1.04	$1.5M
24.11.21	SELL	ARKG	140,573	$1.62	$227.7K
24.11.20	SELL	ARKG	425,234	$1.61	$684.6K
24.11.19	SELL	ARKG	376,997	$1.51	$569.3K
24.11.18	SELL	ARKG	397,130	$1.50	$595.7K
24.11.12	SELL	ARKG	314,865	$2.05	$645.5K

03.18SELL

189

ARKGClose$0.96Est. total$182

03.13SELL

1,437

ARKGClose$0.93Est. total$1.3K

03.12SELL

12,801

ARKGClose$0.93Est. total$11.9K

03.11SELL

102,053

ARKGClose$0.97Est. total$99.0K

03.10SELL

136,193

ARKGClose$0.99Est. total$134.8K

03.09SELL

186,633

ARKGClose$0.99Est. total$184.0K

03.06SELL

397,382

ARKGClose$0.99Est. total$393.5K

03.05SELL

129,759

ARKGClose$1.02Est. total$132.4K

03.04SELL

473,801

ARKGClose$1.06Est. total$502.2K

03.03SELL

1,484,403

ARKGClose$1.04Est. total$1.5M

11.21SELL

140,573

ARKGClose$1.62Est. total$227.7K

11.20SELL

425,234

ARKGClose$1.61Est. total$684.6K

11.19SELL

376,997

ARKGClose$1.51Est. total$569.3K

11.18SELL

397,130

ARKGClose$1.50Est. total$595.7K

11.12SELL

314,865

ARKGClose$2.05Est. total$645.5K

1 / 2

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 1 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Andreas HalvorsenViking Global Investors

Maintained

58,651,170

Portfolio Weight

0.2%

Est. Value

$75M

vs Prev Quarter

Maintained

Sold · Q4 2025

Cathie WoodARK Invest

Fully Sold

Portfolio Weight

Prev Holdings

189

Est. Sold Value

$185.92

Holding Period

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Hold

Analyst Targets

avg.

$1.35

vs Current ▲ +101.5% upside

Current$0.67

Low ~ High$1.35 ~ $1.35

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

TD Cowen

Hold

$1.35

+101.49%

—

Maintain

2025-11-05

Keybanc

Sector Weight

N/A

—

Downgrade

2025-02-27

TD Cowen

Buy

$2.50

+273.13%

—

Maintain

2024-10-31

TD Cowen

Buy

$2.75

+310.45%

—

Maintain

2024-08-01

TD Cowen

Buy

$3.50

+422.39%

—

Upgrade

2024-04-16

1 / 2

Avg Target

$1.35

vs Current ▲ +101.5% upside

Hold

1 analysts

Hold 1

Low $1.35

Current $0.67

High $1.35

Firm	Position	Target	Upside	Close	Action	Date
TD Cowen	Hold	$1.35	+101.49%	—	Maintain	25.11.05
Keybanc	Sector Weight	N/A	N/A	—	Downgrade	25.02.27
TD Cowen	Buy	$2.50	+273.13%	—	Maintain	24.10.31
TD Cowen	Buy	$2.75	+310.45%	—	Maintain	24.08.01
TD Cowen	Buy	$3.50	+422.39%	—	Upgrade	24.04.16

1 / 2

Price Information

Previous Close$0.65

Open$0.63

Day Range$0.63 - $0.69

52-Week Range$0.63 - $1.72

1-Year Change-45.97%

Trading Volume

Volume3,538,692

Avg Volume (3mo)3,465,335

Valuation

Market Cap262.6M

Book Value$1.38

Shares Outstanding392,578,808

Financials

Revenue (TTM)84.6M

Net Income-53,934,000

EPS$-0.13

EBITDA-53,072,000

Profitability

P/E Ratio-

P/B Ratio0.49

Return on Equity (ROE)-11.18%

Return on Assets (ROA)-6.61%

Profit Margin100.36%

EV/EBITDA3.50

Beta1.40

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)16.67

Company Overview

Standard BioTools Inc. develops, manufactures, and sells instrumentation, consumables, and services for proteomics and genomics research. Their key platforms, including SomaScan, CyTOF, Hyperion, and Biomark X9, enable scientists to analyze proteins and genes for drug development and understanding disease mechanisms. The company serves academic institutions and biopharmaceutical companies globally.

P/B

0.49

Below book value

ROE

-11.2%

Net loss

Beta

1.40

Market Volatility

RSI(14)

16.7

Oversold

AI-generated summary. Not investment advice.

Standard BioTools Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks